Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial

被引：4

作者：

Gupta, Vikas ^{[1
]}

Oh, Stephen ^{[2
]}

Devos, Timothy ^{[3
,4
]}

Dubruille, Viviane ^{[5
]}

Catalano, John ^{[6
,7
]}

Somervaille, Tim C. P. ^{[8
,9
]}

Platzbecker, Uwe ^{[10
]}

Giraldo, Pilar ^{[11
]}

Kosugi, Hiroshi ^{[12
]}

Sacha, Tomasz ^{[13
]}

Mayer, Jiri ^{[14
]}

Illes, Arpad ^{[15
]}

Ellis, Catherine ^{[16
]}

Wang, Zhaohui ^{[16
]}

Gonzalez Carreras, Francisco J. ^{[17
]}

Strouse, Bryan ^{[16
]}

Mesa, Ruben ^{[18
]}

机构：

[1] Princess Margaret Canc Ctr, Toronto, ON, Canada

[2] Washington Univ, Sch Med, St Louis, MO USA

[3] Univ Hosp Leuven, Dept Hematol, Leuven, Belgium

[4] Katholieke Univ Leuven, Lab Mol Immunol, Rega Inst, Dept Microbiol & Immunol, Leuven, Belgium

[5] CHU Nantes, Nantes, France

[6] Monash Univ, Frankston, Australia

[7] Frankston Hosp, Frankston, Australia

[8] Christie NHS Fdn Trust, Manchester, Lancs, England

[9] Canc Res UK Manchester Inst, Manchester, Lancs, England

[10] Univ Leipzig, Clin Hematol Cellular Therapy & Hemostaseol, Leipzig, Germany

[11] Hosp Quironsalud, Dept Hematol, Zaragoza, Spain

[12] Ogaki Municipal Hosp, Dept Hematol, Ogaki, Japan

[13] Jagiellonian Univ Hosp, Krakow, Poland

[14] Univ Hosp Brno, Brno, Czech Republic

[15] Univ Debrecen, Div Haematol, Dept Internal Med, Fac Med, Debrecen, Hungary

[16] GSK Plc, Philadelphia, PA USA

[17] GSK Plc, Stevenage, Herts, England

[18] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA

来源：

LEUKEMIA & LYMPHOMA | 2024年 / 65卷 / 07期

关键词：

Anemia; hemoglobin; momelotinib; myelofibrosis; ruxolitinib; transfusion independence;

D O I：

10.1080/10428194.2024.2328800

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A key hallmark of myelofibrosis is anemia, which ranges from mild to severe based on hemoglobin levels. To more clearly define outcomes with the Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor momelotinib by anemia severity, we performed a descriptive post hoc exploratory analysis of the double-blind, randomized, phase 3 SIMPLIFY-1 study (NCT01969838; N = 432, JAK inhibitor naive, momelotinib vs. ruxolitinib); subgroups were defined by baseline hemoglobin: <10 (moderate/severe), <greater than or equal to>10 to <12 (mild), or <greater than or equal to>12g/dL (nonanemic). Spleen and symptom results were generally consistent with those previously reported for the intent-to-treat population. In anemic subgroups, momelotinib was associated with higher rates of transfusion independence and reduced/stable transfusion intensity vs. ruxolitinib. No new or unexpected safety signals were identified. Overall, momelotinib provides spleen, symptom, and anemia benefits to JAK inhibitor-naive patients with myelofibrosis regardless of baseline hemoglobin level, and greater anemia-related benefits vs. ruxolitinib in patients with hemoglobin <12g/dL.

引用

页码：965 / 977

页数：13